53840-29-2

Upstream product

• 3709-08-8 3,3'-dimethylbutyrolactone 
• 64-17-5 ethanol 
• 107-04-0 1-Bromo-2-chloroethane 
• 97-62-1 Ethyl isobutyrate 

Downstream Products

• 1431139-40-0 p-tolyl 2-O-(2,2-dimethyl-4-azidobutanoyl)-3,4-di-O-benzyl-1-thio-α-L-rhamnopyranoside 
• 1431139-38-6 p-tolyl 2-O-(2,2-dimethyl-4-azidobutanoyl)-3,4,6-tri-O-benzyl-1-thio-β-D-glucopyranoside 

Relevant academic research and scientific papers

Divergent Total Syntheses of Yaequinolone-Related Natural Products by Late-Stage C-H Olefination

Divergent total syntheses of 10 yaequinolone-related natural products have been achieved for the first time by late-stage C-H olefination of 3,4-dioxygenated 4-aryl-5-hydroxyquinolin-2(1H)-ones, core structures of this family of natural products. A robust synthetic methodology to construct the core structures has been established, and the C-H olefination reaction has been carried out with synthetically useful yields and high levels of site-selectivity under mild reaction conditions in the presence of a Pd/S,O-ligand catalyst.

CONJUGATED INHIBITORS OF DNA DAMAGE RESPONSE

Provided herein are releasable conjugates of inhibitors of DNA damage response suitable for use as therapeutic agents in the treatment of disease.

IMPROVED CONJUGATION LINKERS

Provided are β-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers.

2,2-dimethyl-4-(4-methoxy-phenoxy) butanoate and 2,2-dimethyl-4-azido butanoate: Two new pivaloate-ester-like protecting groups

The title compounds were developed to extend the available orthogonalities within the class of protecting groups removed by assisted cleavage. The mild, complementary (oxidative vs reductive) reaction conditions for the removal, together with their pivalo

An oxidative approach to a hydroxypiperidinone utilizing a Rh-catalyzed C-H activation process

C-H activation and isomerization using a Rh-catalyst provided quick access to dehydropiperidine derivatives that could be further oxidized to hydroxypiperidinone derivatives.

One-pot synthesis of 3,3-dimethylpyrrolidine-2-carbonitriles from 4-chloro-2,2-dimethylbutanal in water

Treatment of 4-chloro-2,2-dimethylbutanal, prepared in high yield by means of a three-step procedure starting from ethyl isobutyrate, with successively sodium bisulphite, a primary amine and potassium cyanide in water afforded novel 1-alkyl- and l-aryl-3,

Synthetic studies on condensed-azole derivatives. V. Synthesis and anti- asthmatic activities of ω-sulfamoylalkyloxy[1,2,4]triazolo[1,s-b]pyridazines

A series of novel ([1,2,4]triazolo[1,5-b]pyridazin-6- yl)oxyalkylsulfonamides was synthesized and evaluated for the ability to inhibit platelet activating factor (PAF)-induced bronchoconstriction in guinea pigs. The compounds bearing a gem-dialkyl or a cycloalkylidene group at the 2 position of the sulfamoylpropyloxy group in the side chain and a methyl group at the 7 position were found to have potent activity. Among them, 2,2-diethyl-3-(7-methyl[l,2,4]-triazolo[1,5-b]pyridazin-6- yl)oxypropanesulfonamide (13) showed excellent anti-asthmatic activity. Compouds 13 may be of significant value in the treatment of asthma and other respiratory diseases. The structure-activity relationships in this series of compounds are discussed.

Triazolopyridazine compounds, their production and use

Novel compound represented by the formula: STR1 wherein R1 stands for H, an optionally substituted lower alkyl group or a halogen; R2 and R3 respectively stands for a hydrogen or an optionally substituted lower alkyl group, or R2 and R3 may, taken together with the adjacent --C=C-- group, form a 5- to 7-membered ring; X stands for O, SO or SO2 ; Y stands for a group of the formula: STR2 (R4 and R5 respectively stand for H or an optionally substituted lower alkyl group) or a divalent group derived from an optionally substituted 3- to 7-membered homocyclic or heterocyclic ring; R6 and R7 each stands for H, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group or an optionally substituted aryl group, or R6 and R7 may, taken together with the adjacent N, form an optionally substituted N-containing heterocyclic group; m stands for 0 to 4; n stands for 0 to 4, or a salt thereof, which has excellent anti-PAF activities anti-LTC4 activities and anti-ET-1 activities, and is of value as an antiasthmatic agent, and their production, intermediates and pharmasceutical compositions.